RoosterBio, Inc, a biotechnology market disrupter and leading supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, released the Regenerative Medicine industry’s first human umbilical cord (hUC) MSC paired cell and media system designed for product development and bringing with it an unprecedented step-change in quantifiable productivity metrics. RoosterVial™-hUC-MSC-XF, allows scientists to generate billions of perinatal cells in a fraction of the time when paired with RoosterBio’s existing xeno-free (XF) hMSC plug and play systems. This product line is the only commercially available, high-volume perinatal MSC bioprocess system with a line of sight to towards clinical translation. [Read more…]
Global Cord Blood Corporation (CO) Positioned to Merge with Cordlife Group in Asia
Global Cord Blood Corporation (NYSE: CO) announced June 4, 2019, that its board of directors received a non-binding proposal letter from Cordlife Group Limited for the two companies to combine by way of a statutory merger. Under the terms of the nonbinding proposal, Cordlife will issue its ordinary shares at SGD0.5 per ordinary share, and in exchange, will receive all of the outstanding ordinary shares of Global Cord Blood Corporation (GCBC) at US$7.50 per share. [Read more…]
ExCellThera enters into a manufacturing and collaboration agreement with New York Blood Center
MONTREAL, MAY 7, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has entered into a manufacturing and collaboration agreement with Comprehensive Cell Solutions (CCS), a division of New York Blood Center (NYBC) for the clinical grade production of ExCellThera’s lead cell therapy product, ECT-001. [Read more…]
Famicord, Europe’s Largest Cord Blood Bank, and India’s CelluGen, Sign Letter of Intent
FamiCord Group, the largest cord blood bank in Europe, and CelluGen Biotech, a biotech company headquartered in Gurgaon, India, have signed a letter of intent (LOI) to cooperate across a range of business activities. Dated April 25, 2019, the specifics of the LOI state that the companies will pursue cooperation within the “field of family cord blood banking of stem cells and the use of stem cells in experimental and standard therapies.” The companies may jointly develop ATMPs and drugs. [Read more…]
ExCellThera’s Cell Expansion Technology, ECT-001, Receives FDA RMAT Designation
MONTREAL, April 23, 2019 — ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to its lead technology, ECT-001, in the treatment of hematologic malignancies. The RMAT designation is based on strong data from Phase I/II clinical trials using ECT-001 to expand stem and immune cells for the treatment of blood cancers. [Read more…]
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 33
- Next Page »